125 related articles for article (PubMed ID: 19377291)
1. Cervarix, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions.
Le Tallec D; Doucet D; Elouahabi A; Harvengt P; Deschuyteneer M; Deschamps M
Hum Vaccin; 2009 Jul; 5(7):467-74. PubMed ID: 19377291
[TBL] [Abstract][Full Text] [Related]
2. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine.
Deschuyteneer M; Elouahabi A; Plainchamp D; Plisnier M; Soete D; Corazza Y; Lockman L; Giannini S; Deschamps M
Hum Vaccin; 2010 May; 6(5):407-19. PubMed ID: 20953154
[TBL] [Abstract][Full Text] [Related]
3. Development of a highly thermostable, adjuvanted human papillomavirus vaccine.
Hassett KJ; Meinerz NM; Semmelmann F; Cousins MC; Garcea RL; Randolph TW
Eur J Pharm Biopharm; 2015 Aug; 94():220-8. PubMed ID: 25998700
[TBL] [Abstract][Full Text] [Related]
4. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
5. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
6. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
Schwarz TF
Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the thermal stability of Gardasil.
Shank-Retzlaff ML; Zhao Q; Anderson C; Hamm M; High K; Nguyen M; Wang F; Wang N; Wang B; Wang Y; Washabaugh M; Sitrin R; Shi L
Hum Vaccin; 2006; 2(4):147-54. PubMed ID: 17012891
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the thermal stability and the protective efficacy of spray-dried HPV vaccine, Gardasil® 9.
Kunda NK; Peabody J; Zhai L; Price DN; Chackerian B; Tumban E; Muttil P
Hum Vaccin Immunother; 2019; 15(7-8):1995-2002. PubMed ID: 30883270
[TBL] [Abstract][Full Text] [Related]
9. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
10. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach.
Garçon N; Morel S; Didierlaurent A; Descamps D; Wettendorff M; Van Mechelen M
BioDrugs; 2011 Aug; 25(4):217-26. PubMed ID: 21815697
[TBL] [Abstract][Full Text] [Related]
11. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
12. Thermostability of a trivalent, capsomere-based vaccine for human papillomavirus infection.
Dong M; Meinerz NM; Walker KD; Garcea RL; Randolph TW
Eur J Pharm Biopharm; 2021 Nov; 168():131-138. PubMed ID: 34438020
[TBL] [Abstract][Full Text] [Related]
13. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
Schwarz TF
Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
[TBL] [Abstract][Full Text] [Related]
14. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.
Einstein MH; Levin MJ; Chatterjee A; Chakhtoura N; Takacs P; Catteau G; Dessy FJ; Moris P; Lin L; Struyf F; Dubin G;
Hum Vaccin Immunother; 2014; 10(12):3455-65. PubMed ID: 25483700
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
[TBL] [Abstract][Full Text] [Related]
16. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant.
Pedersen C; Petaja T; Strauss G; Rumke HC; Poder A; Richardus JH; Spiessens B; Descamps D; Hardt K; Lehtinen M; Dubin G;
J Adolesc Health; 2007 Jun; 40(6):564-71. PubMed ID: 17531764
[TBL] [Abstract][Full Text] [Related]
17. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer.
Monie A; Hung CF; Roden R; Wu TC
Biologics; 2008 Mar; 2(1):97-105. PubMed ID: 19707432
[TBL] [Abstract][Full Text] [Related]
18. Non-clinical safety assessment of single and repeated intramuscular administration of a human papillomavirus-16/18 vaccine in rabbits and rats.
Segal L; Morelle D; Kaaber K; Destexhe E; Garçon N
J Appl Toxicol; 2015 Dec; 35(12):1577-85. PubMed ID: 25752809
[TBL] [Abstract][Full Text] [Related]
19. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
[TBL] [Abstract][Full Text] [Related]
20. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
